Biognosys Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
85
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$92.7M
Biognosys General Information
Description
Developer of generation proteomics tools designed to transform life science research for highly multiplexed protein quantification. The company's proteomics tools are based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach that decodes the proteome and equips researchers from all fields with a deep view of protein expression in cells, tissues, or body fluids, enabling researchers and scientists to access valuable information on their protein analysis needs.
Contact Information
Website
www.biognosys.com(Operating Subsidiary)
Corporate Office
- Wagistraße 21
- Schlieren
- 8952 Zurich
- Switzerland
Corporate Office
- Wagistraße 21
- Schlieren
- 8952 Zurich
- Switzerland
Biognosys Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Merger/Acquisition | 03-Jan-2023 | $92.7M | Completed | Generating Revenue | ||
| 12. Later Stage VC (Series G) | 08-Aug-2019 | Completed | Generating Revenue | |||
| 11. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 10. Later Stage VC (Series C) | 12-Jul-2017 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 23-Dec-2015 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 22-May-2015 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | Completed | Startup | ||||
| 6. Early Stage VC (Series A) | 07-Dec-2012 | Completed | Startup | |||
| 5. Grant | 21-Feb-2012 | $1.63M | $2.87M | Completed | Startup | |
| 4. Early Stage VC (Series A) | 31-Oct-2011 | $2.87M | $2.87M | Completed | Startup |
Biognosys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series G | ||||||||
| Series F | ||||||||
| Series E | ||||||||
| Series D | 3,603,488 | $0.48 | $0.48 | 1x | $0.48 | 6.44% | ||
| Preference | 9,634,868 | $0.43 | $0.43 | 1x | $0.43 | 17.23% |
Biognosys Comparisons
Industry
Financing
Details
Biognosys Competitors (28)
One of Biognosys’s 28 competitors is Preomics, a Venture Capital-Backed company based in Munich, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Preomics | Venture Capital-Backed | Munich, Germany | ||||
| ProMab Biotechnologies | Private Equity-Backed | Richmond, CA | ||||
| Abcam | Corporate Backed or Acquired | Cambridge, United Kingdom | ||||
| Twist Bioscience | Formerly VC-backed | South San Francisco, CA | ||||
| ProSci (Biotechnology) | Private Equity-Backed | Poway, CA |
Biognosys Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Biognosys Patents
Biognosys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4767352-A1 | System and method for targeted analysis of diagonal family of dia-pasef acquisition methods | Pending | 24-Aug-2023 | ||
| WO-2025040781-A1 | System and method for targeted analysis of diagonal family of dia-pasef acquisition methods | Inactive | 24-Aug-2023 | ||
| EP-4369345-A1 | System and method for optimizing analysis of dia data by combining spectrum-centric with peptide-centric analysis | Inactive | 14-Nov-2022 | ||
| EP-4587841-A1 | Methods to determine drug target residence time and to select best drug-target candidates | Active | 14-Sep-2022 | ||
| EP-4587841-B1 | Methods to determine drug target residence time and to select best drug-target candidates | Active | 14-Sep-2022 | G01N33/6848 |
Biognosys Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Biognosys Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BioMedPartners | Venture Capital | Minority | ||
| InnoVentures Lab | Accelerator/Incubator | Minority | ||
| PM Equity Partner | Corporate Venture Capital | Minority | ||
| Redalpine | Venture Capital | Minority | ||
| Syngenta Crop Protection (Switzerland) | Corporate Venture Capital | Minority |
Biognosys FAQs
-
When was Biognosys founded?
Biognosys was founded in 2008.
-
Where is Biognosys headquartered?
Biognosys is headquartered in Zurich, Switzerland.
-
What is the size of Biognosys?
Biognosys has 85 total employees.
-
What industry is Biognosys in?
Biognosys’s primary industry is Discovery Tools (Healthcare).
-
Is Biognosys a private or public company?
Biognosys is a Private company.
-
What is the current valuation of Biognosys?
The current valuation of Biognosys is .
-
What is Biognosys’s current revenue?
The current revenue for Biognosys is .
-
How much funding has Biognosys raised over time?
Biognosys has raised $22M.
-
Who are Biognosys’s investors?
BioMedPartners, InnoVentures Lab, PM Equity Partner, Redalpine, and Syngenta Crop Protection (Switzerland) are 5 of 7 investors who have invested in Biognosys.
-
Who are Biognosys’s competitors?
Preomics, ProMab Biotechnologies, Abcam, Twist Bioscience, and ProSci (Biotechnology) are some of the 28 competitors of Biognosys.
-
When was Biognosys acquired?
Biognosys was acquired on 03-Jan-2023.
-
Who acquired Biognosys?
Biognosys was acquired by Bruker.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
